AstraZeneca PLC (AZN) Stock Profile & Financial OverviewAstraZeneca PLC
AZN Company Overview & Business Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Key Information
Current Trend for AZN
An assessment of the current trend environment for AZN, based on the latest closing price data and intended to describe the market context heading into the next trading session.
As of 2025-12-24, the current trend for AZN is an Indeterminate Transition Phase (Unclear Direction).
Daily and weekly trends are conflicting, reducing directional conviction and making directional trading less favorable at this stage.
- The weekly backdrop provides strong tailwinds, confirming that the medium-term path of least resistance is upward.
- Price is currently trending at a healthy distance, sitting 1.79 ATR away from the adaptive KAMA baseline.
- Technical Update: Price has breached a key Fractal High, confirming a structural breakout to the upside.
Explore More Data
Adaptive Trend Model · Daily & Weekly (2025-12-24 ET)
This model uses an adaptive trend algorithm based on daily and weekly price data to identify whether a stock is in an uptrend, downtrend, or consolidation over a multi-week to multi-month horizon. Compared with traditional moving-average systems, it filters short-term noise more effectively, captures trend continuation more reliably, and provides a stronger basis for position sizing and risk-management decisions such as stop-loss and take-profit levels.
As of 2025-12-24, AZN in a non-directional consolidation; Long-term trend is bullish.
Trend Strength: AZN last closed at 92.45, trading 1.2 ATR above the adaptive KAMA baseline (90.78). Technical Classification: Non-Directional / Range-Bound.
Trend Score: Technical Score: 35/100. Classification: Sideways. Alignment: Indeterminate. Logic: Price action is range-bound or lacking sufficient slope for trend confirmation.
SuperTrend Risk: Structural Support: Adaptive SuperTrend at 87.07. This level serves as the calculated invalidation point for the current upward structure.
Risk Skew: Multi-timeframe risk skew is currently assessed as Non-Directional. Price is oscillating within a low-momentum range. Risk is two-sided, favoring mean-reversion strategies over trend-following.
Key Levels: Key technical references: Spot 92.45, KAMA 90.78.